Thioridazine: Alternative and Potentially Effective Therapy of the XDRTB Patient

Author(s): Leonard Amaral, Marta Martins, Miguel Viveiros

Journal Name: Letters in Drug Design & Discovery

Volume 8 , Issue 2 , 2011

Become EABM
Become Reviewer


Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.

There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.

Keywords: Macrophage activation, MDR-TB, Phenothiazines, Therapy, Thioridazine, XDR-TB, Pulmonary tuberculosis infections, Mycobacterium tuberculosis, thioridazine therapy, mycobacteria bind, pneumocyte II, isoniazid, rifampicin, kanamycin, amikacin, capreomycin, psychosis, syphilis, narcotize, colorless neuroleptic chlorpromazine, neuroleptic thioridazine

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [130 - 132]
Pages: 3
DOI: 10.2174/157018011794183860
Price: $65

Article Metrics

PDF: 6